Literature DB >> 7562923

Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.

M H Cynamon1, R Gimi, F Gyenes, C A Sharpe, K E Bergmann, H J Han, L B Gregor, R Rapolu, G Luciano, J T Welch.   

Abstract

A series of substituted pyrazinoic acid esters has been prepared and examined for their in vitro activity against Mycobacterium avium and Mycobacterium kansasii as well as Mycobacterium tuberculosis. Modification of both the pyrazine nucleus and the ester functionality have been very successful in expanding the activity of pyrazinamide to include M. avium and M. kansasii, organisms normally not susceptible to pyrazinamide. Several of these compounds have activities 100-1000-fold greater than that of pyrazinamide against M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562923     DOI: 10.1021/jm00020a003

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

2.  Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.

Authors:  David Pires; Emília Valente; Marta Filipa Simões; Nuno Carmo; Bernard Testa; Luís Constantino; Elsa Anes
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

3.  Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.

Authors:  Oren Zimhony; Catherine Vilchèze; Masayoshi Arai; John T Welch; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

4.  Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide.

Authors:  Z Sun; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  In vitro antimycobacterial activity of 5-chloropyrazinamide.

Authors:  M H Cynamon; R J Speirs; J T Welch
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Synthesis and biological activity of alkynoic acids derivatives against mycobacteria.

Authors:  Catherine Vilchèze; Lawrence W Leung; Robert Bittman; William R Jacobs
Journal:  Chem Phys Lipids       Date:  2015-08-06       Impact factor: 3.329

7.  High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.

Authors:  Jean-Philippe Lanoix; Rokeya Tasneen; Paul O'Brien; Jansy Sarathy; Hassan Safi; Michael Pinn; David Alland; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.

Authors:  Silvana C Ngo; Oren Zimhony; Woo Jin Chung; Halimah Sayahi; William R Jacobs; John T Welch
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

9.  Ester-prodrugs of ethambutol control its antibacterial activity and provide rapid screening for mycobacterial hydrolase activity.

Authors:  Erik M Larsen; Dominique C Stephens; Nathan H Clarke; R Jeremy Johnson
Journal:  Bioorg Med Chem Lett       Date:  2017-08-30       Impact factor: 2.823

Review 10.  Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance.

Authors:  Erik M Larsen; R Jeremy Johnson
Journal:  Drug Dev Res       Date:  2018-10-10       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.